Malaysia Pharmaceuticals Market, By Type (Pharmaceutical Drugs v/s Biologics), By Drug Classification (Branded Drugs v/s Generic Drugs), By Mode of Purchase (Prescription-Based Drugs v/s Over-the-counter Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, Competition, Forecast and Opportunities, 2018-2028
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationMalaysia Pharmaceuticals Market, By Type (Pharmaceutical Drugs v/s Biologics), By Drug Classification (Branded Drugs v/s Generic Drugs), By Mode of Purchase (Prescription-Based Drugs v/s Over-the-counter Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, Competition, Forecast and Opportunities, 2018-2028
Malaysia pharmaceuticals
As per the International Trade Administration (ITA), the number of active internet users in Malaysia rose from 27.4 million to 80% by 2021 and mobile phone penetration was high at 84.2%. In Malaysia, there were 28 million active users on social media and 39.9 million cellular connections in January 2021.
Growing focus on healthcare by government organization
currently, it is anticipated that healthcare will account for around 7.25% of the nation's GDP. This is anticipated to rise as a result of population growth, an increase in life expectancy, and rising government spending on better healthcare infrastructure and services.
Rising Prevalence of Chronic Diseases
According to the National Health and Morbidity Survey (NHMS) 2019, the prevalence of overweight and obesity among adults in Malaysia has been on the rise, with 30.0% of adults being overweight and 17.5% being obese.
Recent Development
- In April 2023, Amway(Malaysia) Holdings Berhad (AMWAY Malaysia) launched the Gut Reset-WeightManagement educational and awareness nationwide campaign to strengthen further itsefforts to address non-communicable diseases (NCDs). For the financial yearended December 31, 2022, AMWAY Malaysia set a new revenue record of RM1,514.8million which was up 1.9% compared to what it had achieved in the previousfiscal year. The strong demand for products in the areas of health andwellness, as well as personal care under the lead with nutrition program hasled to an increase in sales.
- In April 2023, Novartis started 2023 with great growth and to increaseproductivity, the organization would give "high value" drugs apriority across five core categories, including cardiovascular and neurology.
Download Free Sample Report
Market Segmentation
The Malaysia pharmaceuticals market is segmented into type, drug classification, mode of purchase, distribution channel, and company. Based on type, the Malaysia pharmaceutical market is divided into pharmaceutical drugs and biologics. Based on drug classification, the Malaysia pharmaceutical market is categorized into branded drugs and generic drugs. Based on mode of purchase, the Malaysia pharmaceutical market is categorized into prescription-based drugs and over-the-counter drugs. Based on distribution channel, the Malaysia pharmaceutical market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. Based on region, the Malaysia pharmaceutical market is segmented into East Malaysia and West Malaysia.
Company Profiles
Abbvie, Inc., Astrazeneca Plc, Bristol Myers Squibb Co., GSK plc, Johnson & Johnson, Merck & Co, Novartis Ag, Pfizer Inc., Roche Holding Ag, and Sanofi
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, volume forecasting, Company shares, competitive landscape, growth factors, and trends |
| Segments covered | Type Drug Classification Mode of Purchase Distribution Channel Region |
| Country scope | East Malaysia, West Malaysia |
| Key companies profiled | Abbvie, Inc., Astrazeneca Plc, Bristol Myers Squibb Co., GSK plc, Johnson & Johnson, Merck & Co, Novartis Ag, Pfizer Inc., Roche Holding Ag, and Sanofi. |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy